

# Single-nucleotide Fc $\gamma$ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Jonathan C. Strefford,<sup>1,\*</sup> Malgorzata Nowicka,<sup>2,\*</sup> Chantal E. Hargreaves,<sup>1,3,\*</sup> Cathy Burton,<sup>4</sup> Andrew Davies,<sup>5</sup> Rosalind Ganderton,<sup>6</sup> Wolfgang Hiddemann,<sup>7</sup> Chisako Iriyama,<sup>8</sup> Wolfram Klapper,<sup>9</sup> Kate V. Latham,<sup>1</sup> Maurizio Martelli,<sup>10</sup> Farheen Mir,<sup>11</sup> Helen Parker,<sup>1</sup> Kathleen N. Potter,<sup>1</sup> Matthew J. J. Rose-Zerilli,<sup>1</sup> Laurie H. Sehn,<sup>12,13</sup> Marek Trněný,<sup>14</sup> Umberto Vitolo,<sup>15</sup> Christopher R. Bolen,<sup>16</sup> Christian Klein,<sup>17</sup> Andrea Knapp,<sup>2</sup> Mikkel Z. Oestergaard,<sup>2</sup> and Mark S. Cragg<sup>1,18</sup>

<sup>1</sup>School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; <sup>2</sup>F. Hoffmann-La Roche Ltd, Basel, Switzerland; <sup>3</sup>Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; <sup>4</sup>Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds, United Kingdom; <sup>5</sup>Southampton Cancer Research United Kingdom (CRUK)/National Institute of Health Research (NIHR) Experimental Cancer Medicines Centre, University of Southampton, Southampton, United Kingdom; <sup>6</sup>Southampton University Hospitals National Health Service (NHS) Foundation Trust, Southampton, United Kingdom; <sup>7</sup>Department of Medicine III, Ludwig-Maximilians University Hospital Munich, Munich, Germany; <sup>8</sup>Department of Pathology and Tumor Biology, Nagoya Graduate School of Medicine, Nagoya University, Nagoya, Japan; <sup>9</sup>Department of Hematopathology, University of Kiel, Kiel, Germany; <sup>10</sup>Department of Translational and Precision Medicine, Section of Hematology, Sapienza University, Rome, Italy; <sup>11</sup>Royal Marsden Hospital, London, United Kingdom; <sup>12</sup>BC Cancer Centre for Lymphoid Cancer; <sup>13</sup>Department of Medicine, University of British Columbia, Vancouver, BC, Canada; <sup>14</sup>1st Department of Medicine, 1st Faculty of Medicine, Charles University General Hospital, Prague, Czech Republic; <sup>15</sup>Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy; <sup>16</sup>Genentech, Inc., South San Francisco, CA; <sup>17</sup>Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland; and <sup>18</sup>Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University of Southampton, Southampton, United Kingdom

## Key Points

- Fc $\gamma$ R genotype is not associated with response to obinutuzumab/rituximab combined with chemotherapy in untreated patients with FL or DLBCL.

Single-nucleotide polymorphisms (SNPs) have been shown to influence Fc $\gamma$  receptor (Fc $\gamma$ R) affinity and activity, but their effect on treatment response is unclear. We assessed their importance in the efficacy of obinutuzumab or rituximab combined with chemotherapy in untreated advanced follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the GALLIUM ([www.clinicaltrials.gov](http://www.clinicaltrials.gov) #NCT01332968) and GOYA (#NCT01287741) trials, respectively. Genomic DNA was extracted from patients enrolled in GALLIUM (n = 1202) and GOYA (n = 1418). Key germline SNPs, *FCGR2A* R131H (rs1801274), *FCGR3A* F158V (rs396991), and *FCGR2B* I232T (rs1050501), were genotyped and assessed for their impact on investigator-assessed progression-free survival (PFS). In both cohorts there was no prognostic effect of *FCGR2A* or *FCGR3A*. In FL, *FCGR2B* was associated with favorable PFS in univariate and multivariate analyses comparing I232T with I232I, with a more modest association for rituximab-treated (univariate: hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.54-1.14; *P* = .21) vs obinutuzumab-treated patients (HR, 0.56; 95% CI, 0.34-0.91; *P* = .02). Comparing T232T with I232I, an association was found for obinutuzumab (univariate: HR, 2.76; 95% CI, 1.02-7.5; *P* = .0459). Neither observation retained significance after multiple-test adjustment. *FCGR2B* was associated with poorer PFS in multivariate analyses comparing T232T with I232I in rituximab- but not obinutuzumab-treated patients with DLBCL (HR, 4.40; 95% CI, 1.71-11.32; *P* = .002; multiple-test-adjusted *P* = .03); however, this genotype was rare (n = 13). This study

Submitted 7 December 2020; accepted 3 April 2021; published online 29 July 2021.  
DOI 10.1182/bloodadvances.2020003985.

\*J.C.S., M.N. and C.E.H. share first authorship.

Presented in part at the 60th annual meeting of the American Society of Hematology, San Diego CA, 1-5 December 2018 (Abstract P-1409).

Qualified researchers may request access to individual patient-level data through the clinical study data request platform (<https://vivli.org/>). Further details on Roche's

criteria for eligible studies are available here (<https://vivli.org/members/ourmembers/>). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here ([https://www.roche.com/research\\_and\\_development/who\\_we\\_are\\_how\\_we\\_work/clinical\\_trials/our\\_commitment\\_to\\_data\\_sharing.htm](https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)).

The full-text version of this article contains a data supplement.

© 2021 by The American Society of Hematology

shows that Fc $\gamma$ R genotype is not associated with response to rituximab/obinutuzumab plus chemotherapy in treatment-naive patients with advanced FL or DLBCL.

## Introduction

Obinutuzumab is a humanized, glycoengineered, type II anti-CD20 antibody with enhanced direct cell killing and antibody-dependent cellular phagocytosis and cytotoxicity (ADCC) compared with type I anti-CD20 antibodies, such as rituximab.<sup>1-5</sup> Obinutuzumab has been approved for the first-line treatment of chronic lymphocytic leukemia, in combination with chlorambucil; follicular lymphoma (FL), in combination with chemotherapy followed by obinutuzumab maintenance, and in combination with bendamustine followed by obinutuzumab maintenance for relapsed/rituximab-refractory FL.<sup>6-8</sup>

Fc $\gamma$  receptors (Fc $\gamma$ Rs), of which there are 6 in humans, encoded by the *FCGR1A*, *FCGR2A*, *FCGR2B*, *FCGR2C*, *FCGR3A*, and *FCGR3B* genes, are critical mediators of anti-CD20 monoclonal antibody (mAb)-mediated cell killing.<sup>9</sup> Activating Fc $\gamma$ R (Fc $\gamma$ RI, Fc $\gamma$ RIIa, Fc $\gamma$ RIIc, and Fc $\gamma$ RIIIa) deliver immunoreceptor tyrosine-based activation motif-mediated active signaling, capable of driving cytotoxic granule release (leading to ADCC) and/or antibody-dependent cellular phagocytosis from various cellular effectors, including natural killer cells, macrophages, monocytes, and neutrophils. In contrast, Fc $\gamma$ RIIb, the sole inhibitory Fc $\gamma$ R, impairs this signaling through Src homology 2 domain-containing inositol phosphatase- and Src homology 2-containing tyrosine phosphatase-1-mediated phosphatase activation.<sup>10</sup>

Importantly, the Fc $\gamma$ R genes are highly polymorphic, exhibiting multiple single-nucleotide polymorphism (SNP) and copy number variation events (reviewed in Hargreaves et al<sup>11</sup>). The R131H and F158V SNPs in *FCGR2A* and *FCGR3A*, respectively, have been shown to alter affinity for different subclasses of immunoglobulin G,<sup>12,13</sup> which, in the case of the high-affinity *FCGR3A* 158V allele, leads to clear enhancement of natural killer cell-mediated ADCC at lower mAb concentrations.<sup>14</sup> Other SNPs, such as *FCGR2B* I232T appear to affect receptor activity by impairing inhibitory signaling,<sup>15</sup> but have yet to be definitively assessed in the context of anticancer mAb activity, due to their low prevalence.<sup>11</sup>

Although the impact of these SNPs on Fc $\gamma$ R function has been demonstrated in vitro,<sup>16</sup> their influence on overall patient response is less clear. Initial retrospective studies, based on low numbers of patients, suggested that the *FCGR3A* and *FCGR2A* genotypes affect the efficacy of rituximab. Cartron et al showed inferior response rates for the *FCGR3A* 158F genotype compared with 158V carriers in 49 patients with FL treated with rituximab.<sup>17</sup> In a retrospective cohort, Weng and Levy demonstrated improved response rates and more durable remissions in 87 rituximab-treated patients with FL with the *FCGR3A* V158V and *FCGR2A* H131H genotypes, compared with F and R carriers, respectively.<sup>18</sup> Finally, in a small cohort of rituximab-treated patients with FL or mantle cell lymphoma, Ghielmini et al reported that patients with *FCGR3A* V158V exhibited superior event-free survival among patients with FL.<sup>19</sup> More recent analyses have failed to identify an impact of *FCGR2A* and *FCGR3A* genotypes in rituximab-treated patients with FL. The RESORT (www.clinicaltrials.gov; #NCT00075946) and PRIMA (#NCT00140582) trials and a retrospective cohort of

newly diagnosed patients all failed to show an influence of the *FCGR2A* R131H and *FCGR3A* F158V genotypes on patient outcome after rituximab and chemotherapy.<sup>20-22</sup> Similarly, data from previously published studies demonstrated that *FCGR2A* and *FCGR3A* genotype status did not correlate with treatment response in patients with diffuse large B-cell lymphoma (DLBCL).<sup>23-25</sup> The inconsistent effects reported by these multiple cohort studies are likely due to their limited size, the heterogeneity of the cohorts, and the variation in the use of rituximab (monotherapy vs combination therapy, first vs second/subsequent line, among others).<sup>17,19-22,26-30</sup>


To overcome these limitations and to provide definitive results of the impact of these SNPs on anti-CD20 mAb therapy, large, prospective, uniform studies using carefully designed SNP assays are needed. Accordingly, we retrospectively analyzed data from 2 recently completed, large (>1000-patient) phase 3 studies, to assess the potential impact of these Fc $\gamma$ R genotypes on the efficacy of obinutuzumab or rituximab in combination with chemotherapy in patients with previously untreated advanced FL (GALLIUM; www.clinicaltrials.gov/ #NCT01332968)<sup>6</sup> or DLBCL (GOYA; #NCT01287741).<sup>31</sup>

## Methods

### Study design, patients, and treatments

GALLIUM and GOYA were phase 3, multicenter, open-label, randomized studies. Full details of their design and primary end points have been published.<sup>6,31</sup> In GALLIUM, patients with previously untreated advanced-stage FL were randomized to receive either obinutuzumab- or rituximab-based immunochemotherapy, followed by maintenance with the same antibody in the responders.<sup>6</sup> The chemotherapy arm (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP]; cyclophosphamide, vincristine, and prednisone [CVP], or bendamustine) was selected by each study center (33.2%, 9.7%, and 57.1%, respectively). In GOYA, previously untreated patients with DLBCL were randomly assigned to receive eight 21-day cycles of obinutuzumab or rituximab plus 6 or 8 cycles of CHOP.<sup>31</sup> The number of CHOP cycles for both arms was agreed on in advance with each study site. If only 6 CHOP cycles were administered, the antibody was administered as monotherapy during cycles 7 and 8. The primary end point for both studies was investigator-assessed progression-free survival (PFS).<sup>6,31</sup> Both studies were conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and all applicable local laws and regulations. The study protocols and amendments and other study-related materials were approved by institutional review boards or ethics committees at the participating centers. Written informed consent was provided by all patients.

A total of 1202 and 1418 patients enrolled in the GALLIUM and GOYA studies, respectively, were included in this study, with updated clinical data available for 1202 and 1414 patients, respectively.<sup>32,33</sup> Of these, 55 and 97 patients could not be genotyped because of lack of consent, lack of blood samples, or DNA extraction failure (Figure 1). Median duration of follow-up was 57.4



**Figure 1. CONSORT diagrams.** (A) Patients with FL in the GALLIUM trial and (B) patients with DLBCL in the GOYA trial. Q2S, Q2Solutions.

months (range, 0.0-77.4 months) in GALLIUM and 47.7 months (range, 0.1-78.2 months) in GOYA.

### Sample preparation, Fc $\gamma$ R genotyping, and molecular confirmation

Genomic DNA was extracted from whole blood from 2222 trial patients by UK Q2Solutions with Autopure, using Genra

Purgene Kits (Qiagen). Nucleic acid extraction and genotyping were performed as previously described.<sup>34</sup> DNA was quantified with UV absorbance and quality was controlled with 260/280 optical density ratio measurements prior to dilution to the appropriate concentration in distilled water. For genotyping, sample triplicates were prepared using the CAS-1200 polymerase chain reaction (PCR) setup robot (Corbett Life Science, Qiagen); amplification and allelic discrimination were performed with a

**Table 1. Baseline demographics and disease characteristics of patients randomized to the GALLIUM and GOYA trials**

Characteristic	GALLIUM (n = 1202)	GOYA (n = 1414)
Treatment: R/G	601 (50.0)/601 (50.0)	710 (50.2)/704 (49.8)
Median age, y (range)	59 (23-88)	62 (18-86)
Sex, male	563 (46.8)	750 (53.0)
Ann Arbor stage III/IV*†	1092 (90.8)	1073 (75.9)
<b>Geographic region</b>		
Asia	185 (15.4)	514 (36.4)
Eastern Europe	157 (13.1)	196 (13.9)
Western Europe	581 (48.3)	426 (30.1)
North America	152 (12.7)	216 (15.3)
Other	127 (10.6)	62 (4.4)
<b>Number of chemotherapy cycles</b>		
6	–	1045 (73.9)
8	–	369 (26.1)
<b>Chemotherapy</b>		
Bendamustine	686 (57.1)	–
CHOP	399 (33.2)	–
CVP	117 (9.7)	–
<b>FLIPI score‡</b>		
Low	106 (9.1)	–
Intermediate	584 (50.1)	–
High	475 (40.8)	–
<b>IPI category</b>		
Low	–	282 (19.9)
Low-intermediate	–	500 (35.4)
High-intermediate	–	412 (29.1)
High	–	220 (15.6)
<b>COOs</b>		
GCB	–	540 (57.9)
ABC	–	243 (26.1)
Unclassified	–	150 (16.1)
<b>BCL2 by IHC  </b>		
Negative	–	392 (51.9)
Positive	–	363 (48.1)

Data are number of patients (percentage of the total study group) unless otherwise specified.

ABC, activated B-cell; CVP, cyclophosphamide, vincristine, and prednisone; FLIPI, FL International Prognostic Index; G, obinutuzumab; GCB, germinal center B-cell; IHC, immunohistochemistry; IPI, International Prognostic Index; R, rituximab.

\*Data missing for 7 patients (GALLIUM).

†Data missing for 1 patient (GOYA).

‡Data missing for 37 patients (GALLIUM).

§Data missing for 481 patients (GOYA).

||Data missing for 659 patients (GOYA).

Corbett Rotor-Gene 6000 (Corbett Life Science) and Rotor-Gene Q series Software 2.0.2 (Build 4), respectively. The SNPs, *FCGR2A* R131H (rs1801274), *FCGR3A* F158V (rs396991), and *FCGR2B* I232T (rs1050501), were genotyped with commercially available (C\_9077561\_20 and C\_25815666\_10) and custom-designed TaqMan discrimination

**Table 2. Prevalence of key FcγR genotypes in the GALLIUM and GOYA trials**

Genotype	GALLIUM*			GOYA†		
	Total	R	G	Total	R	G
<b>FCGR2A</b>	n = 1144	n = 571	n = 573	n = 1316	n = 658	n = 658
R131R	231 (20.2)	117 (20.5)	114 (19.9)	291 (22.1)	138 (21.0)	153 (23.3)
R131H	547 (47.8)	270 (47.3)	277 (48.3)	595 (45.2)	282 (42.9)	313 (47.6)
H131H	366 (32.0)	184 (32.2)	182 (31.8)	430 (32.7)	238 (36.2)	192 (29.2)
<b>FCGR2B</b>	n = 1062	n = 532	n = 530	n = 1080	n = 546	n = 534
I232I	823 (77.5)	406 (76.3)	417 (78.7)	773 (71.6)	396 (72.5)	377 (70.6)
I232T	220 (20.7)	116 (21.8)	104 (19.6)	282 (26.1)	137 (25.1)	145 (27.2)
T232T	19 (1.8)	10 (1.9)	9 (1.7)	25 (2.3)	13 (2.4)	12 (2.3)
<b>FCGR3A</b>	n = 1144	n = 571	n = 573	n = 1313	n = 656	n = 657
F158F	479 (41.9)	256 (44.8)	223 (38.9)	591 (45.0)	285 (43.5)	306 (46.6)
F158V	521 (45.5)	238 (41.7)	283 (49.4)	574 (43.7)	296 (45.1)	278 (42.3)
V158V	144 (12.6)	77 (13.5)	67 (11.7)	148 (11.3)	75 (11.4)	73 (11.1)

Data are number of patients (percentage of the subgroup).


G, obinutuzumab; R, rituximab.

\*Data missing for GALLIUM (n): *FCGR2A*, 58 (total), 30 (R), and 28 (G); *FCGR2B*, 140 (total), 69 (R), 71 (G); *FCGR3A*, 58 (total), 30 (R), 28 (G).

†Data missing for GOYA (n): *FCGR2A*, 98 (total), 52 (R), 46 (G); *FCGR2B*, 334 (total), 164 (R), 170 (G); *FCGR3A*, 101 (total), 54 (R), 47 (G).

assays (Life Technologies, Paisley, United Kingdom), according to the manufacturer's instructions. Quality control samples were included in each batch as follows: known *FCGR2A*, *FCGR3A* and *FCGR2B* wild-type homozygotes, heterozygotes, homozygote variants (Coriell Cell Repository, Camden, NJ), and nontemplate negative control. For a small number of Chinese patients (n = 242), DNA extraction and subsequent *FCGR2A* and *FCGR3A* genotyping were performed by Q2Solutions in China (ViiA 7 Real-Time PCR System; Applied Biosystems-Life Technologies, Carlsbad, CA).

Sanger sequencing using the FcγR-gene-specific PCR primers (supplemental Table 1) was performed for samples that failed TaqMan assays or as a confirmatory step. PCR products were purified using the MinElute 96 UF PCR purification kit (Qiagen) or the ExoSAP method (ExoSAP-IT protocol 2000; USB Corporation, Cleveland, OH), and SNPs were confirmed by Sanger sequencing (Source BioScience, Cambridge, United Kingdom), as previously described.<sup>34</sup> Approximately 10% of the samples were randomly selected for confirmatory sequencing. As they can be technically challenging to identify, we also confirmed all *FCGR2B* non-II genotypes using the same Sanger approach. Genotyping by Taqman assay for *FCGR2A*, *FCGR2B*, and *FCGR3A* failed in 1% to 2%, 4% to 5%, and 13% to 16% of samples, respectively. *FCGR2A* and *FCGR3A* genotypes by TaqMan assay were confirmed in 100% and 99% of cases by Sanger sequencing, respectively. For *FCGR2B*, the II genotype was confirmed in 100% of cases, and the non-II genotypes were confirmed in 85% to 89% of cases. The final *FCGR2A* and *FCGR3A* genotypes were reported as per the TaqMan assay result, except for those cases that failed genotyping, where the Sanger result was utilized. The final *FCGR2B* genotype was reported as the TaqMan assay result where cases were discordant with Sanger sequencing.<sup>34</sup>




**Figure 2. PFS.** Data show PFS in patients with the *FCGR2A* 131 (A), *FCGR2B* 232 (B), or *FCGR3A* 158 (C) SNP genotype with FL treated with rituximab (R) or obinutuzumab (G) plus chemotherapy in the GALLIUM trial.

### Statistical analysis

For both trials, the effect of SNP genotype on investigator-assessed PFS was evaluated per treatment arm and for the pooled treatment

arms. The SNP effect, expressed as a hazard ratio (HR) with 95% confidence interval (CI), was estimated in a univariate Cox proportional hazards regression analysis adjusted for treatment arm and a





**Figure 3.** Forest plot representing survival analysis and the impact of the  $Fc\gamma$  receptor genotypes on PFS per treatment arm. (A) Patients with FL in the GALLIUM trial; (B) patients with DLBCL in the GOYA trial. Time to event was defined by PFS (in days). All analyses were unadjusted and unstratified. Variables for the univariate analysis included biomarker and treatment arm. *P*-value (for hypothesis testing of whether the biomarker effect was equal to 0) was calculated with the Wald test. Adjusted *P*-values were corrected for multiple comparisons by the Benjamini and Hochberg method. Adj, adjusted; G, obinutuzumab; R, rituximab.

multivariate Cox regression analysis adjusted for stratification factors (GALLIUM: follicular lymphoma (FL) International Prognostic Index [FLIPI], chemotherapy regimen; GOYA: geographic region, International Prognostic Index [IPI], number of CHOP cycles). In GOYA, adjustments were also made for cell of origin (COO) and BCL2 protein expression, which have been shown to be prognostically significant in DLBCL.<sup>31,35</sup> The analysis of pooled data additionally accounted for the treatment arm. SNP effect in the prognostic analysis was assessed by using the Wald test at a 5% level. Multiple test correction was performed with the Benjamini and Hochberg methodology. The Kaplan-Meier method was used to estimate PFS distribution for genotypes in each treatment arm.

## Results


### Patients and genotyping results

Patient demographic and disease characteristics for the FL and DLBCL patient populations in the GALLIUM and GOYA trials, respectively, are summarized in Table 1. These characteristics, including the prevalence of each  $Fc\gamma$ R genotype (Table 2), were

comparable across trials and across treatment arms. The prevalence of  $Fc\gamma$ R genotypes by ethnicity in GALLIUM and GOYA are presented in supplemental Table 2. A higher frequency of patients with the *FCGR2B* 232T allele were observed in the Asian populations of both GALLIUM and GOYA, compared with the White population (supplemental Table 2). Of note, because of missing data for COO and BCL2, the number of samples included in the multivariate Cox regression analyses were ~50% and 97% of those included in the univariate analyses in GOYA and GALLIUM, respectively.

### Prognostic effect of $Fc\gamma$ R genotype in patients with FL from the GALLIUM trial

In FL, no significant association was found between PFS and genotypes of either *FCGR2A* or *FCGR3A* (Figures 2 and 3; supplemental Figure 1). For obinutuzumab, the PFS curve for patients with *FCGR3A* V158V was above that for those with F158V and F158F, but this finding is attributable to the statistical variation caused by the lower number of patients with V158V. Only *FCGR2B* was associated with superior PFS in univariate analyses of pooled treatment arms comparing the I232T with the I232I genotype (HR, 0.69; 95%



**Figure 4. PFS.** Data show PFS according to *FCGR2A* 131 (A), *FCGR2B* 232 (B), and *FCGR3A* 158 (C) SNP genotype for patients with DLBCL treated with rituximab (R) or obinutuzumab (G) plus chemotherapy in the GOYA trial.

CI, 0.51-0.93;  $P = .01$ ), with a more modest association for rituximab-treated patients (HR, 0.78; 95% CI, 0.54-1.14;  $P = .21$ ) compared with obinutuzumab-treated patients (HR, 0.56; 95% CI, 0.34-0.91;  $P = .02$ ; Figure 3; supplemental Figure 1). A similar effect was observed in the multivariate analyses (supplemental Figure 1). When comparing the T232T and I232I genotypes, obinutuzumab was associated with a worse prognosis in the univariate analysis (HR, 2.76; 95% CI, 1.02-7.5;  $P = .0459$ ). However, the sample size and number of events for the T232T genotype were very low at 9 and 4, respectively. Neither observation retained statistical significance after  $P$ -value adjustment for multiple comparison.

### Prognostic effect of FcγR genotype in patients with DLBCL enrolled in the GOYA trial

In the patients with DLBCL enrolled in GOYA, PFS results similar to those of patients enrolled in GALLIUM were observed (Figure 4). There was no evidence of a univariate prognostic effect for any FcγR genotype (Figures 3 and 4; supplemental Figure 2). However, in the multivariate analysis, there was an association in the rituximab treatment arm with the *FCGR2B* T232T SNP (HR, 4.40; 95% CI, 1.71-11.32;  $P = .002$ ; multiple-test adjusted  $P = .03$ ) compared with the *FCGR2B* I232I SNP. However, this observation should be interpreted with caution, given the low prevalence of this genotype ( $n = 6$ ; supplemental Figure 2). The multivariate analysis also showed an initial association in the rituximab treatment arm with the *FCGR2A* R131H SNP (HR, 0.57; 95% CI, 0.33-0.99;  $P = .047$ ) compared with the *FCGR2A* R131R SNP; however, this was not significant after  $P$ -value adjustment for multiple tests (adjusted  $P = .282$ ). There was no association between any of the FCGR genotypes and COO in the GOYA trial (supplemental Table 3), and no significant association of the FcγR genotypes with PFS was observed when stratified by COO (supplemental Table 4).

## Discussion

We explored the clinical significance of the 3 well-described FcγR SNPs, *FCGR2A* R131H (rs1801274), *FCGR3A* F158V (rs396991), and *FCGR2B* I232T (rs1050501), in 2 large, international trials (GALLIUM<sup>6</sup> and GOYA<sup>31</sup>) comparing the efficacy and safety of obinutuzumab and rituximab in combination with chemotherapy in treatment-naïve patients with FL and DLBCL. As our cohort included many more patients than previously published studies, our analyses provided greater statistical power to establish the clinical importance of these FcγR genotypes. After analyzing the FcγR genotype status in 2464 patients with indolent and aggressive lymphoma and available DNA, we identified no clear prognostic impact for any of these FcγR SNPs in patients treated with immunochemotherapy.

As considerable inconsistency remains in the literature regarding the prognostic importance of FcγR SNPs, we performed our analysis on 2464 clinical trial patients. The analysis of GALLIUM and GOYA provided the ideal opportunity to (1) evaluate the importance of the 3 best-understood functional FcγR SNPs in a homogeneous cohort of rituximab-treated patients, and (2) to perform a novel assessment of the impact of FcγR SNPs on obinutuzumab-treated patients with FL or DLBCL. Our findings are definitive in this context and further demonstrate the importance of prospective clinical trials for the accurate evaluation of putative biomarkers. The main strengths of the present study were (1) the cost-effective genotyping approach, which

permitted the analysis of a number of candidate SNPs at high sensitivity; (2) the size and homogeneous nature of both cohorts, enabling us to overcome many of the limitations befalling previous studies (eg, inadequate statistical power and heterogeneous study cohorts); and (3) the prospective nature of the patient cohorts, permitting assessment of the impact of FcγR SNPs on disease pathophysiology at multiple survival end points. The main limitation of our study was the targeted nature of our analysis, focusing on only the 3 most well-characterized FcγR SNPs. As such, we did not evaluate the importance of other functionally relevant FcγR SNPs (eg, those in promoters regulating gene expression), nor did we assess the importance of germline CNV, which is known to target key FcγR genes.<sup>11</sup> Furthermore, our analysis of nontumoral DNA precluded the detection of somatic FcγR gene alterations. For example, it has been demonstrated that the *FCGR2B* locus is targeted by focal somatic duplications in DLBCL, which are associated with increased gene transcription and poor patient survival.<sup>36</sup> We also failed to assess the integrated nature of these various FcγR changes (eg, assessing the combined impact of the 3 FcγR SNPs), largely due to insufficient sample size, even in these large trials (the largest of their kind to date designed to assess the efficacy of obinutuzumab and rituximab treatment in combination with chemotherapy). A similar limitation concerns the definitive interpretation of the *FCGR2B* I232T SNP results, given that the T-genotype is so rare, with only ~1% to 2% of patients carrying the TT genotype, it is difficult to make firm conclusions with regard to their impact. This small sample size may explain the apparent reduction in PFS for obinutuzumab- and rituximab-treated T232T patients in GALLIUM and GOYA, respectively. In previous studies, the *FCGR2B* 232T allele was found at a 1% frequency in European populations and varied between a 5% and 11% frequency in African and South East Asian populations.<sup>37,38</sup> The impact of these differences on patient outcomes in ethnically diverse lymphoma cohorts is worthy of further research, particularly in centers across Asia and Africa, where the prevalence of the 232T genotype is higher than in European populations.<sup>37,38</sup> Indeed, our results should be interpreted in the context of the ethnic composition of our cohorts, as our study was not designed to investigate the clinical impact of FcγR SNPs in all ethnicities.

In conclusion, our study, the largest of its type performed to date, provides clear evidence that the FcγR SNPs (*FCGR2A* R131H, *FCGR3A* F158V, and *FCGR2B* I232T) do not confer differential responsiveness to obinutuzumab or rituximab in combination with chemotherapy in treatment-naïve patients with advanced FL or aggressive DLBCL.

## Acknowledgments

The authors thank all patients who participated in and clinicians who contributed to the study; and the Experimental Cancer Medicine Centre (ECMC)–funded University of Southampton Faculty of Medicine Human Tissue Bank (Human Tissue Authority license 12009) for sample storage. Editorial support under the direction of Malgorzata Nowicka was provided by Zoe Toland and Louise Profit of Ashfield MedComms, an Ashfield Health company, and funded by F. Hoffmann-La Roche Ltd.

This work was supported by funding from Bloodwise (grant 12050 and 12036) and Cancer Research United Kingdom (grants A18087, A24721, A25139, and A15581) (M.S.C.), NC3R CRACKIT (grant 15402-106217) (J.C.S. and M.S.C.),



and F. Hoffmann-La Roche Ltd. GALLIUM was sponsored by F. Hoffmann-La Roche Ltd and GOYA was sponsored by F. Hoffmann-La Roche Ltd with the scientific support of the Fondazione Italiana Linfomi.

## Authorship

Contribution: J.C.S., A.D., W.H., W.K., M.M., L.H.S., M.T., U.V., C.R.B., C.K., A.K., M.Z.O., and M.S.C. designed the study; J.C.S., C.E.H., C.B., R.G., C.I., K.V.L., H.P., K.N.P., and M.J.J.R.-Z. conducted the study; C.B., A.D., W.H., M.M., L.H.S., M.T., U.V., C.R.B., C.K., A.K., and M.Z.O. contributed to the recruitment and follow-up of patients; J.C.S., M.N., C.E.H., C.B., A.D., R.G., W.H., C.I., W.K., M.M., H.P., M.J.J.R.-Z., L.H.S., M.T., U.V., C.R.B., C.K., A.K., M.Z.O., and M.S.C. collected the data; J.C.S., M.N., C.E.H., C.I., F.M., H.P., M.J.J.R.-Z., M.Z.O., and M.S.C. analyzed the data; and J.C.S., M.N., F.M., M.Z.O., and M.S.C. interpreted the data.

Conflict-of-interest disclosure: J.C.S. has received research funding from F. Hoffmann-La Roche Ltd. M.N. is an employee of F. Hoffmann-La Roche Ltd. A.D. has received grants and personal fees from F. Hoffmann-La Roche Ltd for serving on advisory boards, honoraria, and travel expenses. W.H. reports consultancy fees, research funding, honoraria, speaker bureau fees, and membership on boards of directors or advisory committees of F. Hoffmann-La Roche Ltd, Janssen, and Gilead. W.K. has received grants from F. Hoffmann-La Roche Ltd, Amgen, Takeda, and Regeneron. M.M. has received personal fees from Gilead Sciences, Novartis, Janssen, F. Hoffmann-La Roche Ltd, Sandoz, and Servier and travel expenses from F. Hoffmann-La Roche Ltd and Servier. F.M. was previously employed by F. Hoffmann-La Roche Ltd. L.H.S. has received consultancy fees from F. Hoffmann-La Roche Ltd, Genentech, Inc., AbbVie, Amgen,

Apobiologix, AstraZeneca, Acerta, Celgene, Gilead Sciences, Janssen, Kite, Karyopharm, Lundbeck, Merck, MorphoSys, Seattle Genetics, Teva, Takeda, TG Therapeutics, and Verastem and research funding from F. Hoffmann-La Roche Ltd and Genentech, Inc. M.T. has received honoraria from Janssen, Gilead Sciences, Takeda, Bristol-Myers Squibb, Amgen, AbbVie, F. Hoffmann-La Roche Ltd, MorphoSys, and Incyte and has served in an advisory role to Celgene. U.V. has received personal fees from Celgene, F. Hoffmann-La Roche Ltd, AbbVie, Gilead Sciences, Janssen, and Regeneron. C.R.B. is employee of Genentech, Inc. and has equity ownership in F. Hoffmann-La Roche Ltd. C.K. is an employee of and has patents with and stock ownership in F. Hoffmann-La Roche Ltd. A.K. is an employee of F. Hoffmann-La Roche Ltd. M.Z.O. is a former employee at Roche with patent royalties in F. Hoffmann-La Roche Ltd and is an employee of Novo Nordisk. M.S.C. reports grants from Cancer Research United Kingdom and Bloodwise, grants and personal fees from Bioinvent, and patents with Bioinvent. The remaining authors declare no competing financial interests.

The current affiliation for M.Z.O. is Novo Nordisk, Zurich, Switzerland.

ORCID profiles: J.C.S., 0000-0002-0972-2881; W.K., 0000-0001-7208-4117; M.J.J.R.-Z., 0000-0002-1064-5350; M.T., 0000-0002-6952-6073; U.V., 0000-0001-7772-2747; M.S.C., 0000-0003-2077-089X.

Correspondence: Jonathan C. Strefford, Cancer Genomics, Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; e-mail: jcs@soton.ac.uk.

## References

1. Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. *Blood*. 2008;112(10):4170-4177.
2. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. *Blood*. 2010;115(22):4393-4402.
3. Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. *Mol Cancer Ther*. 2013;12(10):2031-2042.
4. Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. *Blood*. 2013;122(20):3482-3491.
5. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. *Blood*. 2011;117(17):4519-4529.
6. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. *N Engl J Med*. 2017;377(14):1331-1344.
7. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med*. 2014;370(12):1101-1110.
8. Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. *Lancet Oncol*. 2016;17(8):1081-1093.
9. Dahal LN, Roghanian A, Beers SA, Cragg MS. FcγR requirements leading to successful immunotherapy. *Immunol Rev*. 2015;268(1):104-122.
10. Marshall MJE, Stopforth RJ, Cragg MS. Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? *Front Immunol*. 2017;8:1245.
11. Hargreaves CE, Rose-Zerilli MJ, Machado LR, et al. Fcγ receptors: genetic variation, function, and disease. *Immunol Rev*. 2015;268(1):6-24.
12. Warmerdam PA, van de Winkel JG, Vlugs A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. *J Immunol*. 1991;147(4):1338-1343.

13. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. *Blood*. 1997;90(3):1109-1114.
14. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of Fc gammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. *J Clin Invest*. 1997;100(5):1059-1070.
15. Kono H, Kyogoku C, Suzuki T, et al. Fc gammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. *Hum Mol Genet*. 2005;14(19):2881-2892.
16. Hussain K, Hargreaves CE, Rowley TF, et al. Impact of human Fc gamma R gene polymorphisms on IgG-triggered cytokine release: critical importance of cell assay format. *Front Immunol*. 2019;10:390.
17. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gammaRIIIa gene. *Blood*. 2002;99(3):754-758.
18. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. *J Clin Oncol*. 2003;21(21):3940-3947.
19. Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). *Ann Oncol*. 2005;16(10):1675-1682.
20. Kenkre VP, Hong F, Cerhan JR, et al. Fc gamma receptor 3A and 2A polymorphisms do not predict response to rituximab in follicular lymphoma. *Clin Cancer Res*. 2016;22(4):821-826.
21. Ghesquières H, Cartron G, Seymour JF, et al. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. *Blood*. 2012;120(13):2650-2657.
22. Carlotti E, Palumbo GA, Oldani E, et al. Fc gammaRIIIA and Fc gammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. *Haematologica*. 2007;92(8):1127-1130.
23. Fabisiewicz A, Paszkiewicz-Kozik E, Osowiecki M, Walewski J, Siedlecki JA. Fc gammaRIIA and Fc gammaRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2011;52(8):1604-1606.
24. Ghesquières H, Larrabee BR, Haioun C, et al. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. *Hematol Oncol*. 2017;35(4):447-455.
25. Mitrović Z, Aurer I, Radman I, Ajduković R, Sertić J, Labar B. FC gammaRIIIA and Fc gammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. *Haematologica*. 2007;92(7):998-999.
26. Persky DO, Dornan D, Goldman BH, et al. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. *Haematologica*. 2012;97(6):937-942.
27. Wang SS, Cerhan JR, Hartge P, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. *Cancer Res*. 2006;66(19):9771-9780.
28. Dornan D, Spleiss O, Yeh RF, et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. *Blood*. 2010;116(20):4212-4222.
29. Kim DH, Jung HD, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. *Blood*. 2006;108(8):2720-2725.
30. Weng WK, Weng WK, Levy R. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. *Leuk Lymphoma*. 2009;50(9):1494-1500.
31. Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. *J Clin Oncol*. 2017;35(31):3529-3537.
32. Townsend W, Buske C, Cartron G, et al. Obinutuzumab-based immunochemotherapy prolongs progression-free survival and time to next anti-lymphoma treatment in patients with previously untreated follicular lymphoma: four-year results from the phase III GALLIUM study [abstract]. *Blood*. 2018;132(suppl 1). Abstract 1597.
33. Sehn LH, Martelli M, Trněný M, et al. Final analysis of GOYA: a randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma [abstract]. *Blood*. 2019;134(suppl 1). Abstract 4088.
34. Hargreaves CE, Iriyama C, Rose-Zerilli MJ, et al. Evaluation of high-throughput genomic assays for the Fc gamma receptor locus [published correction appears in *PLoS One*. 2016;11(3):e0145040.]. *PLoS One*. 2015;10(11):e0142379.
35. Tsuyama N, Sakata S, Baba S, et al. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. *Blood*. 2017;130(4):489-500.
36. Arthur SE, Jiang A, Grande BM, et al. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. *Nat Commun*. 2018;9(1):4001.
37. Willcocks LC, Carr EJ, Niederer HA, et al. A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus. *Proc Natl Acad Sci USA*. 2010;107(17):7881-7885.
38. Clatworthy MR, Willcocks L, Urban B, et al. Systemic lupus erythematosus-associated defects in the inhibitory receptor Fc gammaRIIB reduce susceptibility to malaria. *Proc Natl Acad Sci USA*. 2007;104(17):7169-7174.